NEU-411
Asset
Small molecule LRRK2 inhibitor to reduce pathogenic kinase activity in Parkinson's disease
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Autophagy
- 4
- Indications
- 1
- Trial
- 1
- Developer
Indications
4Early Parkinson disease
Phase 2, Recruiting, NCT06680830, clinicaltrials.gov, 7 Oct 2026
Idiopathic Parkinson disease
Phase 2, Recruiting, NCT06680830, clinicaltrials.gov, 7 Oct 2026
Parkinson
Phase 2, Recruiting, NCT06680830, clinicaltrials.gov, 7 Oct 2026
1 more
In the full profile
- Targets and what it contains2
- Owner and partners3
- Trials1
- Evidence for its targets2
- Competitors12
- Aging relevance3
Every asset’s record: target, stage, trials and the evidence behind it.